Company profile: Liquidia
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for pulmonary hypertension. Portfolio includes investigational treprostinil products YUTREPIA (inhaled dry powder) and L606 (sustained-release liposomal via next-generation nebulizer) for PAH and PH-ILD; a fully substitutable generic treprostinil injection for PAH promoted with Sandoz; and PRINT Technology to create precise drug particles for enhanced lung delivery.
Products and services
- YUTREPIA: Investigational inhaled dry‑powder formulation of treprostinil for PAH and PH‑ILD, delivering treprostinil to the lungs using a powder-based route of administration
- Treprostinil Injection: Fully substitutable generic treprostinil for parenteral administration in PAH, containing the same active ingredient and dosage form as Remodulin, promoted in partnership with Sandoz
- PRINT Technology: Proprietary technology creating drug particles with precise, uniform size, shape, and composition to enhance pulmonary drug delivery and deposition in the lungs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Liquidia
Acorda Therapeutics
HQ: United States
Website
- Description: Provider of commercial-stage biopharmaceutical therapies, identifying, developing and commercializing therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other nervous system disorders. Products include INBRIJA (levodopa inhalation powder for Parkinson’s symptoms), AMPYRA (dalfampridine to improve walking in adults with MS), and the ARCUS drug delivery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acorda Therapeutics company profile →
BlueWillow Biologics
HQ: United States
Website
- Description: Provider of intranasal vaccine and adjuvant technologies, including an oil-in-water emulsion Intranasal Adjuvant Technology, NE01 adjuvanted intranasal vaccines, the BW-1010 anthrax vaccine candidate, and a therapeutic peanut allergy vaccine, built on the NanoVax platform to elicit mucosal, cellular, and systemic immunity; also focused on topical antiseptic and anti-infective products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlueWillow Biologics company profile →
Nu-Med Plus
HQ: United States
Website
- Description: Provider of patented medical device technology to safely deliver precision doses of nitric oxide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nu-Med Plus company profile →
Lipocine
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products, including TLANDO, an FDA-approved oral testosterone replacement therapy; LPCN 1111, an oral testosterone prodrug for hypogonadal men; LPCN 1144 and 1148, oral prodrugs of bioidentical testosterone for NASH and cirrhosis symptoms; LPCN 1107, an oral candidate to prevent recurrent preterm birth (FDA orphan drug); and LPCN 1154, an oral neurosteroid for postpartum depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lipocine company profile →
Bioject
HQ: United States
Website
- Description: Provider of needle-free injection therapies to improve administration of liquid medications, including pharmaceuticals, vaccines, and biologics, using technology that forces medication at high speed through a tiny orifice held against the skin, with over 25 years of experience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioject company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Liquidia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Liquidia
2.2 - Growth funds investing in similar companies to Liquidia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Liquidia
4.2 - Public trading comparable groups for Liquidia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →